Mergers & Acquisitions ·
Ultragenyx agrees to sell Rare Pediatric Disease Priority Review Voucher for $203 million
RAREUltragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc. entered into an asset purchase agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) to a buyer for $203 million in cash. The company was awarded the PRV by the U.S. Food and Drug Administration on September 17, 2026, following the approval of FAYUVI (rebisufligene etisparvovec-hopf) for treating pediatric patients with mucopolysaccharidosis type IIIA. The transaction is subject to customary closing conditions, including the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. Ultragenyx Pharmaceutical Inc. operates in the biopharmaceutical industry, focusing on developing treatments for rare genetic diseases.